[Skip to Navigation]
April 1, 2020

At the Leading Edge in Morphea—New Insights Into Disease Course and Management Options

Author Affiliations
  • 1Department of Dermatology, University of California, San Francisco
JAMA Dermatol. 2020;156(5):495-496. doi:10.1001/jamadermatol.2020.0033

Although rarely life-threatening, morphea may be accompanied by substantial morbidity. Symptoms of active disease and functional impairment from damage are associated with decreased quality of life.1 Morphea treatment is ideally tailored to disease subtype and severity, with the goal of controlling active disease and preventing further damage. Evidence-based treatment in morphea has traditionally been limited in light of the rarity of the condition and a lack of standardized outcome measures.2 However, over the last 10 years, the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) has emerged as a useful outcome measure in morphea research given its ease of use and ability to help differentiate disease activity (erythema, induration at edge, and/or progression) from damage (atrophy, dyspigmentation, and/or sclerosis).3

Add or change institution